Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12983729 | 0.79 | KMT2A (0.44) | ALDH1A1CYP1A2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL31703779 | 0.78 | ALDH1A1 (0.50) | ALDH1A1CYP1A2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL436166 | 0.78 | ALDH1A1 (0.50) | ALDH1A1CYP1A2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2081137 | 0.76 | KMT2A (0.57) | ALDH1A1KMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL2079703 | 0.76 | KMT2A (0.57) | ALDH1A1CYP1A2KMT2AMEN1GAA | |
| SCHEMBL29155628 | 0.76 | NR1H3 (0.45) | ALDH1A1CYP1A2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL25278023 | 0.75 | KMT2A (0.57) | ALDH1A1CYP1A2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18539802 | 0.75 | CYP3A4 (0.43) | ALDH1A1CYP1A2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL25322071 | 0.75 | NR1H3 (0.50) | ALDH1A1KMT2AMEN1SMN1; SMN2TNF | |
| SCHEMBL10323011 | 0.75 | RAB9A (0.57) | ALDH1A1CYP1A2KMT2AMAOBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021155748-A1 | INHIBITORS OF MALARIAL AND PLASMODIUM FALCIPARUM HEXOSE TRANSPORTER AND USES THEREOF | TSINGHUA UNIVERSITY (CN) | 2021-08-12 | — | — | WO | disclosed |
| EP-2139891-B1 | 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120196890-A1 | 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | BUNNELLE WILLIAM H (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2455383-A2 | 4 -substituted azaadamantane derivatives and methods of use thereof | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8163915-B2 | Modulate neuronal nicotinic receptor activity; attention deficit disorder, Parkinson's, Tourette's, schizophrenia, cognitive deficits, dementia; acute pain, post-surgical pain, chronic pain, inflammatory pain; 1-azatricyclo[3.3.1.13,7]decan-4-one O-2-naphthyloxime | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2139891-A1 | 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20080255180-A1 | 4-Substituted Azaadamantane Derivatives and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008118745-A1 | 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255180-A1 | 4-Substituted Azaadamantane Derivatives and Methods of Use Thereof | UGT1A4, CYP4B1, CYP4A11 | ALDH1A1 325/4885CYP1A2 76/4885KMT2A 650/4885 |
| US-20120196890-A1 | 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | UGT1A4, CYP4B1, CYP4A11 | ALDH1A1 325/4885CYP1A2 76/4885KMT2A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.